Catégorie : Pharmacologie

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study, Richard J. Huntsman et al., 2019

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study Richard J. Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton1,5, Scott Corley, Robert Laprairie, Andrew W. Lyon, Simona Meier, Darrell D. Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung and Philippe Major Frontiers in  Neurology, 2019, 10:716. doi: 10.3389/fneur.2019.00716   Purpose : There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study. Methods : The study is an open-label, [...]

Lire la suite

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study, Darren Reithmeier et al., 2018

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study Darren Reithmeier, Richard Tang-Wai, Blair Seifert, Andrew W. Lyon, Jane Alcorn, Bryan Acton, Scott Corley, Erin Prosser-Loose, Darrell D. Mousseau, Hyun J. Lim, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Lionel Carmant and Richard J. Huntsman BMC Pediatrics, 2018, 18:221 https://doi.org/10.1186/s12887-018-1191-y   Abstract Background : Initial studies suggest pharmaceutical grade cannabidiol (CBD) can reduce the frequency of convulsive seizures and lead to improvements in quality of life in children affected by epileptic encephalopathies. With limited access to pharmaceutical CBD, Cannabis extracts in oil are becoming increasingly available. [...]

Lire la suite

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome, Blathnaid McCoy et al., 2018

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome Blathnaid McCoy, Laura Wang, Maria Zak, Sameer Al-Mehmadi, Nadia Kabir, Kenda Alhadid, Kyla McDonald, Grace Zhang, Rohit Sharma, Robyn Whitney, Katia Sinopoli & O. Carter Snead III Annals of Clinical and Translational Neurology, 2018, 5, (9), 1077–1088 doi: 10.1002/acn3.621   Abstract Introduction : Both D9 Tetrahydrocannabidiol (THC) and cannabidiol (CBD) components of cannabis, have been shown to have anticonvulsant effects. Cannabis oils are used to treat seizures in drug-resistant epilepsy (DRE). Recent trials provide data on dosing, side effects, and efficacy of CBD, yet there is a paucity of information on THC in epilepsy. Primary [...]

Lire la suite

Priority Considerations for Medicinal Cannabis-Related Research, Marcel O. Bonn-Miller et al., 2019

Priority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045   Keywords : medicinal cannabis; medical marijuana   Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]

Lire la suite

Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes, Santé Canada, dernière version octobre 2018

Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Santé Canada Auteur : Hanan Abramovici Ph.D. Co-auteurs : Sophie-Anne Lamour, Ph.D. et George Mammen, Ph.D. Nous republions cet excellent document de Santé Canada, et surtout, le résumé des indications reconnues, et envisagées, du cannabis thérapeutique.   Aperçu des énoncés récapitulatifs Les énoncés récapitulatifs suivants visent à résumer le contenu des sections 4.0 (Usages thérapeutiques possibles) et 7.0 (Effets indésirables) et leurs sous-sections respectives. Les énoncés récapitulatifs peuvent être également trouvés dans leurs sections et sous-sections respectives dans le corps même du document. Remarque: la plupart des études [...]

Lire la suite

Long-term Heavy Cannabis Use : implications for health education, Niall COGGANS et al., 2004

Long-term Heavy Cannabis Use : implications for health education Niall COGGANS, Phil DALGARNO, Lindsay JOHNSON & David SHEWAN Drugs : education, prevention and policy, 2004, Vol. 11, No. 4, 299–313   ABSTRACT There is growing evidence that cannabis can have negative effects on health. While the ongoing debate about the nature and duration of these effects recognizes mild cognitive impairment, the evidence for irreversibility of cognitive impairment and causal links with psychiatric illness is not conclusive. There is undoubtedly potential for impairment of respiratory functioning, but that will depend on lifetime load and in most cases is confounded with tobacco smoking. There is a [...]

Lire la suite

Acute effects of delta 9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype, Matthijs G. Bossong et al., 2019

Acute effects of delta-9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype Matthijs G. Bossong, Hendrika H. van Hell, Chris D. Schubart, Wesley van Saane, Tabitha A. Iseger, Gerry Jager, Matthias J.P. van Osch, J. Martijn Jansma, René S. Kahn, Marco P. Boks, Nick F. Ramsey European Neuropsychopharmacology, 2019, 13, 56, 1–11 https://doi.org/10.1016/j.euroneuro.2019.03.010   Abstract Cannabis produces a broad range of acute, dose-dependent psychotropic effects. Only a limited number of neuroimaging studies have mapped these effects by examining the impact of cannabis on resting state brain neurophysiology. Moreover, how genetic variation influences the acute effects of cannabis on resting state brain function [...]

Lire la suite

The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population, Anahita Bassir Nia et al., 2019

The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population Anahita Bassir Nia, MD‡; Claire L. Mann, BA; Sharron Spriggs, MA; Daniel R. DeFrancisco, MD; Steven Carbonaro, MD; Lyla Parvez, MA; Igor I. Galynker, MD, PhD; Charles A. Perkel, MD; and Yasmin L. Hurd, PhD Journal of Clinical Psychiatry, 2019, 80, (4), 18m12539 https://doi.org/10.4088/JCP.18m12539 Background : Current evidence suggests that women are more sensitive to the effects of cannabinoids. The aim of this study was to investigate the relevance of sex in the association of synthetic cannabinoid (SC) use with psychosis and agitation. Methods : A [...]

Lire la suite

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review, Albert Batalla et al., 2019

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review Albert Batalla, Hella Janssen, Shiral S. Gangadin and Matthijs G. Bossong Journal of Clinical Medicine, 2019, 8, 1058 doi : 10.3390/jcm8071058 Abstract : The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the ecacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined [...]

Lire la suite

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial, Jose M. Trigo et al., 2018

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial Jose M. Trigo, Alexandra Soliman, Lena C. Quilty, Benedikt Fischer, JuÈrgen Rehm, Peter Selby, Allan J. Barnes11¤a, Marilyn A. Huestis, Tony P. George, David L. Streiner, Gregory Staios, Bernard Le Foll PLoS ONE, 2018, 13, (1), e0190768. https://doi.org/10.1371/journal.pone.0190768   Abstract Background The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex®) can decrease cannabis withdrawal symptoms. Here, we assessed in a pilot study the [...]

Lire la suite